AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 9, 2025 -- Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous system, slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 5 to 9 in San Diego.
Robert J. Fox, M.D., from the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, and colleagues conducted a phase 3, double-blind, event-driven trial involving 1,131 adults (age range, 18 to 60 years) with secondary progressive MS, Expanded Disability Status Scale scores of 3.0 to 6.5, documented evidence of disability progression during the previous 12 months, and no clinical relapses during the 24 months before screening. Participants were randomly assigned to receive tolebrutinib or placebo (754 and 377 individuals, respectively).
The researchers found that compared with placebo, tolebrutinib treatment was associated with a 31 percent risk reduction in six-month confirmed disability progression. Six-month confirmed disability improvement was experienced by more participants with tolebrutinib than placebo (a secondary end point). A slight increase in some adverse events was seen with tolebrutinib versus placebo, including respiratory infections. Rare events of high liver enzyme increases were seen with tolebrutinib, which occurred within 90 days of starting treatment.
"The trial found that treatment with tolebrutinib slows progression of disability in nonrelapsing secondary progressive MS, which is really exciting because this is the very first time we've identified a treatment that is effective for this form of MS," Fox told HealthDay News. "Now there are safety concerns, particularly potential liver injury, and that will require careful counseling of patients who may consider this therapy and close monitoring. But finally, I think a bright day has come for ... secondary progressive MS because we have finally found a treatment that may be helpful."
Several authors disclosed ties to Sanofi, which manufactures tolebrutinib and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Neuromodulation Methods Show Comparable Outcomes for Neurogenic Bladder in Women With MS
WEDNESDAY, May 7, 2025 -- For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic...
Higher Fish Intake Linked to Reduced Risk for MS Disability Worsening
FRIDAY, Feb. 28, 2025 -- Higher fish consumption is associated with slower disability progression in multiple sclerosis (MS), according to a study published online Feb. 25 in the...
Early Childhood Sun Exposure Linked to Lower Risk for Pediatric MS Relapse
WEDNESDAY, Feb. 12, 2025 -- Greater prenatal and early childhood sun exposure is associated with a lower risk for relapse among children with multiple sclerosis (MS), according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.